Table 2.

Sofosbuvir-based regimens in patients with HCV and renal impairment

Ref.	GTs	No. of patients	CKD	Treatment-naïve/cirrhosis	Regimens	SVR12
Taneja et al. [27]	GT1, 42 (65%); GT2, 1 (1%); GT3, 22 (34%)	65	eGFR < 30; HD, 54 (83%)	55 (85%)/21 (32%)	12- or 24-week of 200 mg SOF/60 mg DCV	100% (65/65)
Kumar et al. [28]	GT1a, 17; GT1b, 1; GT3a, 7; GT3b, 1	26	CKD stage 4,5 or HD (eGFR < 30)	19 (73%)/22 (85%)	24-Week of generic SOF/RBV	100% (26/26)
Kumar et al. [28]	GT1a, 22; GT1b, 4	26	CKD stage 4,5 or HD (eGFR < 30)	23 (89%)/20 (77%)	12-Week of generic SOF/LDV	100% (26/26)
Kumar et al. [28]	GT3a, 17; GT3b, 2	19	CKD stage 4,5 or HD (eGFR < 30)	16 (84%)/12 (63%)	12-Week of generic SOF/DCV	100% (19/19)
Sho et al. [29]	GT2	40	CKD stage 3a/3b	29 (73%)/NA	12-Week of SOF/RBV	90% (36/40)

Ref. reference, GTs genotypes, No number, CKD chronic kidney disease, HD hemodialysis, eGFR estimated glomerular filtration rate, SVR12 sustained virological response at 12 weeks, SOF sofosbuvir, DCV daclatasvir, LDV ledipasvir, RBV ribavirin, NA not available